Novartis | NVS - Sales Revenues

Stock Price
144.19
Daily Change
-3.34 -2.26%
Monthly
-4.31%
Yearly
28.48%
Q2 Forecast
142.62

Novartis reported $13.86B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bausch Health Companies USD 2.8B 120M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
J&J USD 24.1B 500M Mar/2026
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 283.44M 9.34M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Sanofi EUR 12.14B 65M Mar/2026
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Zoetis USD 2.4B 0 Dec/2025